Official Title: “Do Dexmedetomidine and Buspirone Synergistically Reduce the Threshold, Gain, and Maximum Intensity of Shivering?”

The purpose of this research is to determine if the combination of buspirone and dexmedetomidine are effective as a treatment to induce therapeutic hypothermia.

The design of the study includes four study days done in random order. The days are as follows: 1) Control (no drug); 2) Buspirone 60 mg orally; 3) Dexmedetomidine (delivered by a computer-controlled IV infusion to a target plasma concentration of 0.6 ng/ml); and, 3) the combination of buspirone 60 mg and dexmedetomidine (target plasma concentration of 0.6 ng/ml). a 20 cm-long catheter will be inserted into a cubital vein using standard aseptic technique In addition to the PIC line catheter, a simple peripheral catheter will be inserted into the other arm for drug administration.

Throughout the study period, mean-skin temperature will be maintained at 31°C by adjusting the temperature of circulating water (Cincinnati Sub-Zero, Cincinnati, OH) and forced-air warmers (Augustine Medical, Inc., Eden Prairie, MN). Furthermore, the back, upper-body, and lower-body will individually be maintained at the designated skin temperature. Lactated Ringer's solution cooled to ≈3°C will be infused via the PIC-line at rates sufficient to decrease tympanic membrane temperature ≈1.5°C/h. Fluid will be administered as long as oxygen consumption or electromyographic intensity (see below) continues to increase or a total of 5 liters of fluid is given. Heart rate will be measured continuously using an electrocardiogram; blood pressure will be determined oscillometrically at 5 min intervals at the ankle. In case heart rate and/or blood pressure changes unexpectedly (by more than 30% of the baseline), the study will stop and the volunteer will be re-warmed immediately.

Study Type: Interventional

Study Design: Treatment, Randomized, Single Blind (Outcomes Assessor), Active Control, Crossover Assignment, Safety/Efficacy Study

Study Primary Completion Date: August 2007

Intervention(s) in this Clinical Trial

• Drug: dexmedetomidine
  • Dexmedetomidine (delivered by a computer-controlled IV infusion to target a plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
• Drug: buspirone
  • Buspirone, 60 mg orally, will be given during controlled hypothermia.
• Drug: Bus and Dex
  • the combination of 60 mg buspirone and dexmedetomidine (target plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
• Drug: Control
  • No drugs given during controlled hypothermia

Arms, Groups and Cohorts in this Clinical Trial

• Experimental: 1
  • dexmedetomidine
• Experimental: 2
  • Buspirone
• Experimental: 3
  • Buspirone and dexmedetomidine
• Placebo Comparator: Control
  • No drug

Primary Measures

• Shivering threshold
• maximum intensity of shivering
• gain of shivering

Secondary Measures

• hemodynamic responses

Inclusion Criteria:

• 18-40 years
• normal weight (BMI <35)
• healthy

Exclusion Criteria:

• obese (BMI >35)
• taking any drugs
• thyroid disease, dysautonomia, or Raynaud's syndrome
• severe claustrophobia

Gender Eligibility for this Clinical Trial: Male

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 40 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers

Lead Sponsor: Outcomes Research Consortium

Overall Clinical Trial Officials and Contacts

Rainer Lenhardt, MD, PhD Principal Investigator University of Louisville School of Medicine  

Information obtained from ClinicalTrials.gov on November 19, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00334360

Study ID Number: Dexmed/Buspirone

ClinicalTrials.gov Identifier: NCT00334360

Health Authority: United States: Institutional Review Board